Adaptive SABR for Prostate Cancer

(RIPCORD Trial)

This trial explores a new method to treat prostate cancer that has spread but still responds to hormone therapy, which lowers male hormones. Researchers aim to understand how adaptive stereotactic ablative radiotherapy (SABR), a precise radiation therapy, can target cancer identified on PSMA PET scans and reduce tumor size and spread. Men with prostate cancer that has spread to 4-20 areas and who plan to receive hormone therapy might be suitable for this study. The trial excludes those who have had previous radiation to the same cancer sites or have certain health conditions that make radiation risky. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on any other PSMA-directed investigational agents for the treatment of the cancer under study.

Research has shown that stereotactic ablative body radiotherapy (SABR) is generally safe and well-tolerated by patients with prostate cancer. One study found SABR effective without causing severe immediate side effects. However, about 15.7% of patients experienced some urinary issues later. Another study suggested that SABR might lead to fewer quality of life side effects compared to typical radiation treatments for prostate cancer. Overall, SABR appears to be a promising and safe treatment option, though some side effects may occur over time.¹²³⁴⁵

Adaptive stereotactic ablative radiotherapy (SABR) is unique because it offers a precise, high-dose radiation treatment that targets cancer cells more accurately than traditional radiotherapy. This precision minimizes damage to surrounding healthy tissue, which is a significant advantage over standard treatments like external beam radiotherapy. Researchers are excited about this approach as it could potentially improve outcomes and reduce side effects for patients with poly-metastatic hormone-sensitive prostate cancer. Additionally, the adaptive nature of SABR allows for real-time adjustments during treatment, enhancing its effectiveness against rapidly changing cancer conditions.

Research has shown that stereotactic ablative radiotherapy (SABR) can effectively treat prostate cancer. For some patients, it has slowed disease progression, with only about 19% experiencing worsening within six months. In another study, SABR significantly reduced prostate-specific antigen (PSA) levels, a marker for monitoring prostate cancer. Some patients saw their PSA levels drop by more than 50%, and a few even had undetectable levels. SABR has also improved outcomes for those with limited cancer spots, suggesting it might control the disease well. Overall, SABR shows promise, especially for prostate cancer that hasn't spread widely. Participants in this trial will receive SABR as part of the study's single treatment arm.³⁵⁶⁷⁸